Schroder Investment Management Group
BCRX icon

Schroder Investment Management Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Schroder Investment Management Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-535,968
Closed -$4.05M – 1153
2025
Q3 		$4.05M Buy
+535,968
New +$4.46M ﹤0.01% 806
2025
Q2 		– Sell
-522,657
Closed -$4.11M – 1166
2025
Q1 		$4.11M Hold
522,657
– – ﹤0.01% 802
2024
Q4 		$3.94M Buy
522,657
+438,887
+524% +$3.33M ﹤0.01% 815
2024
Q3 		$638K Buy
+83,770
New +$637K ﹤0.01% 1081
2020
Q1 		– Sell
-55,420
Closed -$191K – 1306
2019
Q4 		$191K Buy
+55,420
New +$139K ﹤0.01% 1166

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return